Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influence of drug transporter expression on the pharmacokinetics of the HIV protease inhibitor Kaletra (lopinavir/ritonavir) and on the concentration relations between plasma, blood cells, saliva and urine

Trial Profile

Influence of drug transporter expression on the pharmacokinetics of the HIV protease inhibitor Kaletra (lopinavir/ritonavir) and on the concentration relations between plasma, blood cells, saliva and urine

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2009

At a glance

  • Drugs Lopinavir/ritonavir (Primary)
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 12 Feb 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov, last updated 12-2-2009.
    • 12 Feb 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 22 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top